natgillin/translations-raw huggingface dataset:
an LDPC decoder configured to LDPC-decode the L1 signaling data and the depunctured LDPC parity bits; and a BCH decoder configured to BCH-decode the LDPC-decoded L1 signaling data and LDPC parity bits. 
LDPC dekoder konfiguriran za LDPC-dekodiranje signalnih podataka L1 i zatvorenih LDPC paritetnih bitova; i BCH dekoder konfiguriran za BCH dekodiranje LDPC-dekodiranih signalnih podataka L1 i LDPC paritetnih bitova.
The salt according to claim 13, wherein said salt is the L-lactic acid addition salt. 
Sol u skladu s patentnim zahtjevom 13, pri čemu je navedena sol dodatna sol L-mliječne kiseline.
The formulation of claim 1 or 2, wherein diethylene glycol monoethyl ether is present in an amount of 5.0%wt. 
Formulacija prema zahtjevu 1 ili 2, naznačena time, da je navedeni monoctil eter dietilen glikola prisutan u količini od 5.0% tež.
A preferred zwitter ionic buffer that may be used is HEPES (N-(2-Hydroxyethyl)piperazine-N′-2-ethanesulfonic acid) in acid form. 
Preporučeni Zwitterionski pufer koji se može koristiti je HEPES(N-(2-hidroksietil)piperazin-N'-2-etansulfonska kiselina) u kiselinskom obliku.
The method of claim 1, wherein the cumulative total amount of riboflavin per unit volume in said medium is greater than 2.0 mg/L. 
Postupak prema Zahtjevu 1, što je kumulativna ukupna količina riboflavina po jedinici volumena u spomenutom mediju veća od približno 2,0 mg/L.
the group consisting of hexylene glycol, glycerin, propylene glycol, sorbitol, lactic acid, sodium lactate, mannitol, butylene glycol, panthenol, hyaluronic acid, urea, chitosan, polyols, methyl gluceth-10, methyl gluceth-20, and polyethylene glycols; or 
(i) grupe koja se sastoji od heksilen glikola, glicerina, propilen glikola, sorbitola, mliječne kiseline, natrijevog laktata, manitola, butilen glikola, pantenola, hijaluronske kiseline, uree, kitozana, poliola, metil glucet-10, metil glucet-20 i polietilen glikola; ili
Additional methanol (100 mL) was added to the reaction mixture. 
Dodatni metanol (100 mL) je dodan u reakcijsku smjesu.
The tablet according to any one of claims 2 to 4, wherein per 1 part by weight of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, the tablet comprises: 
Tableta u skladu s patentnim zahtjevom 1 ili 2, naznačena time što na 1 težinski dio 7- [4- (4-benzo [b] tiofen-4-il-piperazin-1-il) butoksi] -1H-kinolin-2-on ili njegove soli, tableta sadrži:
FIG. 2 is a schematic partial section of the discharge device with the metered dose valve according to the prior art in the intermediate position; 
prikazuje shematski djelomičan presjek naprave za pražnjenje s ventilom za odmjeravanje doze prema stanju tehnike u međupoložaju; slika 3
A pharmaceutical composition according to claim 1, wherein said HDAC inhibitor is: wherein said pharmaceutical composition is an aqueous liquid; 
. Farmaccutski sastav prema zahtjevu 1, naznačen time, da spomenuti HDAC inhibitor je:
an anchoring system for anchoring the vessel at a predetermined production location and wherein the anchoring system couples the vessel with the bottom proximate the suction location, wherein the lower suction pipe section alone forms the anchoring system and is suitable for use as an anchoring pipe, like e.g. a spud pile, wherein the at least one lower suction pipe section comprises an anchoring portion. Plain suction dredging vessel according to claim 8, wherein the at least one lower suction pipe section comprises at least one suction opening for sucking sludge and the anchoring portion in use extends below the at least one suction opening. 
- sidrišni sustav, namijenjen sidrenju plovila na zadanom mjestu proizvodnje, te gdje sidrišni sustav povezuje plovilo s dnom blizu mjesta usisavanja, gdje sam donji dio usisne cijevi tvori sidrišni sustav i pogodan je za upotrebu kao sidrišna cijev, poput primjerice sidrišnog stupa, gdje najmanje jedan donji dio usisne cijevi sadrži sidrišni dio. Plovilo za jednostavno jaružanje usisavanjem u skladu s patentnim zahtjevom 8, naznačeno time što najmanje jedan donji dio usisne cijevi sadrži najmanje jedan usisni otvor, namijenjen usisavanju mulja, a sidrišni dio se prilikom upotrebe pruža ispod najmanje jednog usisnog otvora.
The nucleic acid molecule according to claim 5, wherein the nucleotide sequences coding for the VH and VL amino acid sequences each is a nucleotide sequence comprising: 
Molekula nukleinske kiseline sukladno patentnom zahtjevu 5, pri čemu kodiranje sekvence nukleotida za svaku od VH i VL sekvenci aminokiseline je sekvenca nukleotida koja sadrži:
a heavy chain variable region CDR1 of SEQ ID NO: 2; a heavy chain variable region CDR2 of SEQ ID NO: 9; a heavy chain variable region CDR3 of SEQ ID NO: 16; a light chain variable region CDR1 of SEQ ID NO: 23; a light chain variable region CDR2 of SEQ ID NO: 30; and a light chain variable region CDR3 of SEQ ID NO: 37; or 
CDR1 varijabilno područje jakog lanca od SEQ ID NO:2; CDR2 varijabilno područje jakog lanca od SEQ ID NO:9; CDR3 varijabilno područje jakog lanca od SEQ ID NO:16; CDR1 varijabilno područje slabog lanca od SEQ ID NO:23; CDR2 varijabilno područje slabog lanca od SEQ ID NO:30; i CDR3 varijabilno područje slabog lanca od SEQ ID NO:37; ili
Accordingly, what is obtained as a result of all this is a premodeled air-tight covering 3, inclusive of channel parts 7 connected (or integrated) therewith, which can subsequently serve for the actual manufacture of the product, for instance a boat hull (Fig. 2). 
S tim u skladu, ono što se dobije kao posljedica svega toga je prethodno oblikovan neprodušan pokrov 3, uključiv dijelove kanala 7 koji su spojeni s njim (ili koji su u njega integrirani), koji mogu kasnije poslužiti za stvarnu izradu proizvoda, na primjer trupa čamca (slika 2).
is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, wherein aryl, heteroaryl and the substituents for aryl and heteroaryl are as defined above; 
je odabran iz skupine koju čine: vodik, C1-C6alkil, C3-C6cikloalkil, aril, supstituirani aril, heteroaril i supstituirani heteroaril, gdje su aril, heteroaril i supstituenti za aril i heteroaril prethodno definirani;
The floating lake system of claim 6, wherein the frame components are constructed out of flexible materials. 
Sustav plutajućeg jezera (1) prema zahtjevu 19, naznačen time što su komponente okvira izrađene od savitljivih materijala.
The antibody, conjugate or pharmaceutical composition for use according to claim 6 or 7, wherein the method further comprises treating with a chemotherapeutic agent, radiation, or a cytokine. 
Antitijelo, konjugat ili farmaceutska kompozicija za uporabu prema patentnom zahtjevu 25 ili 26, pri čemu postupak dalje sadrži liječenje kemoterapeutskim sredstvom, zračenjem ili citokinom.
, R7 and R8 are each independently selected from H, 2H, halo, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C3-7 cycloalkyl and 4-7 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, said C1-3 alkyl optionally substituted with F, OH, C1-3 alkoxy or C1-3 haloalkoxy; or wherein R6 and R8 optionally forms a partially saturated carbobicyclic ring or heterobicyclic ring with the heteroaryl ring, said carbobicyclic ring or heterobicyclic ring optionally substituted with 1 to 3 groups selected from: 2H, halo, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C3-7 cycloalkyl and 4-7 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S. 
, R7 i R8 su svaki zasebno odabrani iz H, 2H, halo, C1-3 alkila, C1-3 haloalkila, C1-3 haloalkoksija, C3-7 cikloalkila i heterociklila s 4 do 7 članova koji ima 1 do 3 heteroatoma odabrana iz N, O i S, pri čemu je spomenuti C1-3 alkil opcionalno supstituiran s F, OH, C1-3 alkoksijem ili C1-3 haloalkoksijem; ili naznačeno time, što R6 i R8 opcionalno formira djelomično zasićeni karbobiciklični prsten ili heterobiciklični prsten s heteroarilnim prstenom, pri čemu je spomenuti karbobiciklični prsten ili heterobiciklični prsten opcionalno supstituiran s 1 do 3 grupe odabrane iz: 2H, halo, C1-3 haloalkila, C1-3 alkoksija, C1-3 haloalkoksija, C3-7 cikloalkila i heterociklila s 4 do 7 članova koji ima 1 do 3 heteroatoma odabrana iz N, O i S.
reacting a compound of formula (II) 
(a) reakciju spoja s formulom (II)
providing a cell culture comprising: mammalian cells that contain a gene encoding TNFR-Fc, which gene is expressed under condition of cell culture; and a defined medium containing glutamine and having at least two medium characteristics selected from the group consisting of: i) a starting amino acid concentration greater than about 70 mM, ii) a molar glutamine to asparagine ratio of less than about 2, iii) a molar glutamine to total amino acid ratio of less than about 0.2, iv) a molar inorganic ion to total amino acid ratio between about 0.4 to 1, and v) a combined glutamine and asparagine concentration greater than about 16 mM; 
dobivanja stanične kulture, koja sadrži: stanice sisavaca, koje sadrže gen koji kodira TNFR-Ig gen, gen koji se ekspresira u uvjetima stanične kulture; i definirani medij, koji sadrži glutamin, a ima najmanje dvije karakteristike medija koje se biraju iz grupe koju čine: polazna koncentracija aminokiselina veća od oko 70 mM,
In vitro release of the active ingredient was determined as in Example 1 and was: Released Time 
Oslobađanje in-vitro djelatne tvari iz pripravka određeno je kao u Primjeru 1 i iznosilo je:
removing the dehydrated organic material from the vacuum chamber. 
uklanjanja posude (38) dehidriranog organskog materijala iz vakuumske komore na kraju (34) za pražnjenje.
In any of the foregoing embodiments, administering the dose of the antisense compound reduces tumor size or tumor volume in the subject. 
Spoj za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što je ukupna tjedna doza protusmislenog spoja u drugoj fazi količina od 200 mg (+12%).
reacting the compound of Formula LXII with a compound of Formula IXa. 
Formula LAI reakciju spoja Formule LXII sa spojem Formule IXa:
or a pharmaceutically acceptable salt thereof. The compound of claim 1 which has formula: wherein the imidazole ring shown in formula A2 is optionally substituted with one or more groups independently selected from halo, haloalkyl, cyano, or alkyl; 
(A4) gdje je prsten imidazola prikazan u formuli A2 i A4 po izboru supstituiran sa jednom ili više grupa koje su nezavisno odabrane od halo, haloalkil, cijano, ili alkil; ili njegova farmaceutski prihvatljiva sol.
Such machines provide the possibility of making a part wherein at least a part of the perimeter of the part comprises said curled edge portion and/or a flange extending transverse—or any other area of the part. 
Takvi strojevi osiguravaju mogućnost izrade dijela kod kojega najmanje jedan dio oboda tog dijela ima navedeni zafrkani rubni predio i/ili prirubnicu koja se pruža poprijeko - ili u bilo koji drugi prostor tog predjela.
A method for making the compound of formula (14): which comprises: 
Postupak za pripremu spoja formule (14): koji sadrži:
The process according to claim 39 wherein said step (c) is performed in a continuous stirred tank reactor. 
Postupak prema patentnom zahtjevu 39 gdje se navedeni korak (c) izvodi u reaktoru - spremniku s kontinuiranim miješanjem.
The tablet of claim 1, wherein the pharmaceutical composition provides a mean maximum plasma concentration (Cmax) of metformin which is from about 10 times to about 20 times the plasma level of the metformin at about 24 hours after administration. 
Farmaceutski sastav sukladno bilo kojem od zahtjeva 1 - 6, pri čemu farmaceutski sastav osigurava srednju maksimalnu koncentraciju u plazmi (Cmax) za metformin koja je oko 10 puta do oko 20 puta razine metformina u plazmi od oko 24 sata nakon primjene.
The compound as claimed in claim 15, wherein Rc1 is C1-6 alkyl substituted by one hydroxyl or cyano group, or a pharmaceutically acceptable salt thereof, or a solvate thereof. 
Spoj u skladu s patentnim zahtjevom 15, naznačen time što je Rc1 C1-6 alkil, supstituiran s jednom hidroksilnom ili skupinom cijano, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
Advantages of the Compositions of the Invention 
Broj objave europskog patenta:
r is an integer ranging from 1 to 10; and s is an integer ranging from 1 to 10; 
r je cijeli broj u opsegu od 1 do 10; i s je cijeli broj u opsegu od 1 do 10;
D-methadone for use according to claim 1, wherein the subject has a central nervous system and the NE receptor is located in the central nervous system. 
D-metadon za uporabu prema zahtjevu 1, naznačen time što subjekt ima središnji živčani sustav i NE receptor se nalazi u središnjem živčanom sustavu.
“ ” is point of attachment; and 
BINA je točka vezivanja; i
A compound according to Formula I: wherein: 
PATENTNI ZAHTJEVI Spoj u skladu s Formulom I:
The use according to any of the preceding claims, wherein said formulation contains one or more active principles. The use according to claim 5, wherein said active principle is selected from corticosteroids, keratolytic agents, non-steroidal anti-inflammatory agents, anti-psoriatic agents, immunosuppressive agents, antiseptic agents, moisturizers, and/or nail strengthening agents. 
Kitozan, naznačen time što je u vodi topljivi hidroksialkilkitozan, i/ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 4, gdje se navedena aktivna tvar bira između kortikosteroida, keratolitika, nesteroidnih protuupalnih sredstava, antipsorijatičnih sredstava, imunosupresivnih sredstava, antiseptičnih sredstava, ovlaživača i/ili sredstava za ojačavanje noktiju.
A compound represented by the formula (IIa): 
Spoj prikazan formulom (IIa):
Such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the cannabinoid receptor modulators in accordance with the invention. 
Takva druga terapeutska sredstva(o) mogu se unositi prije, istodobno sa ili nakon unosa modulatora kanabinoid receptora u skladu sa izumom.
In some embodiments the salt is the 1:1 citrate salt. 
Sol u skladu s patentnim zahtjevom 1, naznačena time što je 1:1 sol.
The transmission method according to claim 1, wherein the first aggregation level value is 1 or 2 and the second aggregation level value is 4 or 8. A transmission apparatus comprising: 
Metoda prijema sukladno jednom od zahtjeva od 1 do 3, naznačena time da je prva vrijednost razine agregacije 2 1 da je druga vrijednost razine agregacije 4 ili 6.
An emulsion formulation for topical application to the skin comprising: an aqueous phase, an oil phase, at least one emulsifier, an Ethylenediamine/NeopentylGlycol/Stearyl Hydrogenated Dimer Dilinoleate Copolymer and at least one sunscreen active agent. 
Pripravak emulzije za lokalnu primjenu na kožu koji sadržava: vodenu fazu, uljnu fazu, najmanje jedan emulgator, etilendiamin/neopentilglikol/stearil hidrogenirani dimer dilinoleat kopolimer 1 najmanje jedno aktivno sredstvo za zaštitu od sunca.
Elastomer product according to any of claims 7 to 9 wherein the material has a thermal conductivity of less than 0.050 W/(mK) at 0 °C and a water vapour diffusion barrier property of at least µ 2000. 
Elastomerni proizvod prema bilo kojem od zahtjeva 7 do 9, naznačen time što materijal ima toplinsku vodljivost manju od 0.050 W/(mK) pri 0°C i svojstvo barijere difuzije vodene pare od najmanje u 2000.
The transmitter of claim 1, wherein the Layer 1 signaling data has Program Specific Information(PSI) and Service Information(SI) reprocessing information for each Physical Layer Pipe (PLP), and the PSI/SI reprocessing information indicates whether or not a PSI/SI reprocessing has been performed. 
Predajnik iz patentnog zahtjeva 1, gdje signalni podaci Razine 1 imaju programski specifičnu informaciju (PSI) i servisnu informaciju (SI) ponovo obrađuju informaciju za svaku cijev fizičke razine (PLP), i ponovna obrada PSI/SI informacija ukazuje je li ili nije provedena ponovna obrada PSISI.
An injection assembly according to claim 6, wherein a spring end stands on the fixed base (554). 
Injekcijski sklop u skladu s patentnim zahtjevom 6, naznačen time što kraj opruge stoji na fiksnom podnožju
The dredge tooth in accordance with claim 1, characterized by an opening (101) for receiving a lock (16) to secure the dredge tooth (14) to the base (12). 
Zub bagera prema zahtjevu 1, naznačen time, da je predviđen otvor (101) za prihvat zasuna (16) u svrhu osiguravanja zuba bagera (14) na bazi (12).
and in which method the resulting compounds are optionally, if appropriate, converted with the corresponding (i) solvents and/or (ii) bases or acids to the solvates, salts and/or solvates of the salts thereof. 
6 H i u navedenom postupku se nastali spoj proizvoljno, ako je prikladno, prevodi s odgovarajućim (i) otapalima i/ili (11) bazama ili kiselinama u solvate, soli i/ili solvate njihovih soli.
Use of the dosage form according to any of claims 1 to 11 for the manufacture of a medicament for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a proton pump inhibitor is indicated. Use according to claim 12, wherein the clinical condition is selected from the group of benign gastric ulcer, gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, duodenal ulcer, duodenal ulcer associated with Helicobacter pylori, prophylaxis of NSAID-associated gastric or duodenal ulcer in patients with an increased risk of gastroduodenal complication who require continued NSAID treatment and combination therapy with antibiotics in the eradication of Helicobacter pylori. 
Dozirni oblik prema bilo kojem od zahtjeva 1 do 10, naznačen time, da se upotrebljava za profilaksu ili liječenje kliničkog stanja kod sisavaca, gdje je kliničko stanje odabrano iz skupine koju čine: benigni gastrični ulkus, bolest gastro-ezofagealnog refluksa, Zollinger-Ellison-sindrom, duodenalni ulkus, duodenalni ulkus povezan s bakterijom Helicobacter pylori, profilaksa za gastrični ili duodenalni ulkus povezan s NSAID kod pacijenata s povećanim rizikom za gastroduodenalne komplikacije, koje zahtijevaju sustavno NSAID liječenje i kombinacijsku terapiju s antibioticima za eradikaciju bakterije Helicobacter pylori.
An audio signal decoding method for decoding an encoded audio signal including a plurality of encoded frames generated from an audio signal including a plurality of frames, using first decoding means operating under a linear predictive coding scheme and second decoding means operating under a coding scheme which is different from the linear predictive coding scheme, the audio signal decoding method comprising: 
Postupak dekodiranja audio signala, namijenjen dekodiranju kodiranog audio signala koji sadrži više okvira, uz pomoć prvog dekodera (24), koji radi prema linearnoj prediktivnoj shemi kodiranja, i drugog dekodera (25), koji radi prema shemi kodiranja koja se razlikuje od linearne prediktivne sheme kodiranja, naznačen time što se postupak dekodiranja audio signala sastoji u:
judgment/total number of mice 
Broj međunarodne objave:
The system of claim 1, including on-board components including a power supply, modem-router, data processor, and an electrical branch monitoring board for connection of the at least one of the current transformer electrical connectors to the switchboard. The system of claim 8, the on-board components further including a memory device to store the acquired electrical data for analysis. 
Sustav prema bilo kojem od prethodnih zahtjeva, koji uključuje komponente za ugradnju na mjestu postavljanja poput izvora struje, modema-rutera, instrumenta za obradu podataka i nadzornu ploču za granu strujnog kruga za spajanje najmanje jednog električnog konektora za strujne transformatore s razvodnom pločom te opcijski memorijski uređaj za pohranu prikupljenih podataka za analizu.
The mouse of claim 6, wherein the human Vk-Jk intergenic region sequence comprises SEQ ID NO: 100. The mouse of claim 1, further comprising an immunoglobulin heavy chain allele comprising human VH, DH, and JH gene segments operably linked to an endogenous mouse heavy chain constant region gene such that the mouse expresses an immunoglobulin heavy chain that comprises a human heavy chain variable domain sequence fused with a mouse heavy chain constant domain. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
A composition comprising at least one conjugate of methylphenidate having a structure selected from the group consisting of 
[image] pri tome X je O; Y je odabrano iz skupine koja se sastoji od O i N;
CDRs are grey-shaded. 
CDR-ovi su osjenčani sivo.
Ivabradine hydrochloride Form IV according to claims 1 to 5 or the pharmaceutical composition according to claims 9 to 11, for use in the treatment of bradycardics, myocardial ischaemia, supraventricular rhythm disturbances, chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm, myocardial infarct, heart failure and associated rhythm disturbances. 
Ivabradin-hidroklorid, Oblik IV, u skladu s patentnim zahtjevima 1 do 5 ili farmaceutski pripravak u skladu s patentnim zahtjevima 9 do 11, naznačeni time što su namijenjeni upotrebi u liječenju bradikardije, ishemije miokarda, supraventrikularnih poremećaja ritma, kronične stabilne angine pektoris kod odraslih osoba s bolešću koronarnih arterija i normalnim sinusnim ritmom, infarkta miokarda, srčane insuficijencije i s njom povezanih poremećaja ritma.
A pharmaceutical aerosol solution composition according to claim 8 wherein the inhalation corticosteroid is selected from the group of beclometasone dipropionate, budesonide or its 22R-epimer, ciclesonide, flunisolide, fluticasone propionate, fluticasone furoate, mometasone furoate, butixocort, triamcinolone acetonide, triamcinolone, methylprednisolone, prednisone, loteprednol and rofleponide; 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 8 u kojem je kortikosteroid za inhalaciju odabran iz skupine od beklometazon-dipropionat, budezonid ili njegov 22R-epimer, ciklezonid, flunizolid, flutikazon-propionat, flutikazon-furoat, mometazon-furoat, butiksokort, triamcinolon-acetonid, triamcinolon, metilprednizolon, prednizon, loteprednol te rofleponid.
The composition of claim 8 wherein the molecule comprises at least a portion of an anti-Fel D1 antibody that specifically binds to Fel D1, fused to at least a portion of an IgG molecule. 
Pripravak u skladu s patentnim zahtjevom 8, naznačen time što molekula sadrži u najmanju ruku dio protutijela protiv Fel D1 koje se specifično veže na Fel D1, fuzioniran s u najmanju ruku dijelom molekule IgG.
The compound, or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof according to claim 1, wherein X is N, CH or C-C1; 
Spoj s formulom: [image] ili njegov ester, zaštićeni spoj na amino na prstenu u 7-bočnom lancu, njegova farmaceutski prihvatljiva sol, ili njegov solvat.
The mixture was hydrogenated for 72h at 3 bar H2. 
Smjesa se hidrogenizira kroz 72 h na 3 bara H,. hidrogenizirana
All over the world a lot of waste-PET (post consumer PET waste) is collected and is just disposed. 
Činjenica je da se svugdje u svijetu puno otpadnog PET-a (PET otpad nastao nakon uporabe) skuplja i jednostavno odbacuje.
Moreover, various foreign ions from the group of the halogens, nonmetals, alkali and alkaline earth metals as well as materials from the transition metals, metalloids and metals can be added to the crystal structure of the phase. These are all suitable for the clinker according to the invention. 
Postupak sukladno zahtjevu 1 ili 2, naznačen time što C5S2$ je stabiliziran dodavanjem jednog ili više stranih iona iz skupine halogena, nemetala, alkalijskih i zemnoalkalijskih metala kao i supstanci iz skupine vodiča i metaloida i metala kristalne strukture.